| NCT ID | NCT06707220 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Baskent University |
| Condition | Heart Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2025-01-08 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2025-01-08 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A comprehensive understanding of the socio-demographic, clinical, and biological characteristics of patients with heart failure is essential to develop novel strategies for improving outcomes. The identification of the barriers to guideline-directed medical therapy implementation in a real-world setting is critical to decreasing the risk of heart failure hospitalization and mortality. A comprehensive and well-designed heart failure registry can determine the clinical characteristics of patients with heart failure, identify patient, physician, and healthcare system-related factors for the non-use of evidence-based therapies, and improve the implementation of guideline-directed medical therapy. It should be noted that the number of heart failure registries that enroll patients with de novo heart failure, chronic heart failure (outpatients), and worsening of heart failure (hospitalized or treated in the emergency department), with all three relevant ejection fraction categories (heart failure with reduced ejection fraction, heart failure with mildly-reduced ejection fraction, and heart failure with preserved ejection fraction), is limited. Furthermore, only a few registries assess detailed aspects of guideline adherence, treatment decisions, and both in-hospital and long-term outcomes. Therefore, the Türkiye Heart Failure (TURK-HF) registry has been designed to address this gap in knowledge about the identification, management, and long-term prognosis of patients with heart failure in a real-world setting.
Eligibility Criteria
Inclusion Criteria: Presence of heart failure - Exclusion Criteria: Age \<18 years \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06707220 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06707220 currently recruiting?
Yes, NCT06707220 is actively recruiting participants. Contact the research team at umutkocabas@hotmail.com for enrollment information.
Where is the NCT06707220 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT06707220 clinical trial?
NCT06707220 is sponsored by Baskent University. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.